(Hypertension. 2002;39:614.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
Cardiac Damage Prevention by Eplerenone: Comparison With Low Sodium Diet or Potassium Loading
From the Endocrinology-Hypertension Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass.
Correspondence to Dr Gail K. Adler, Endocrine-Hypertension Division, Brigham and Women’s Hospital, 221 Longwood Avenue, Boston MA 02115. E-mail gadler{at}partners.org
To determine the extent to which dietary sodium modulates aldosterone-induced cardiovascular damage, and to determine whether increased dietary potassium can prevent this damage, we used the N
-nitro-L-arginine methyl ester (L-NAME)/angiotensin II (Ang II) rat model of cardiac injury. This model is dependent on the presence of aldosterone for the occurrence of myocardial damage. Two sets of experiments were performed. In the first set, the following groups were studied: (1) 1% NaCl to drink (control group); (2) L-NAME/Ang II with water to drink (low salt group); (3) L-NAME/Ang II/1% NaCl (high salt group); (4) L-NAME/Ang II/1% NaCl/eplerenone (eplerenone group). Systolic blood pressure increased similarly in all groups compared with controls. Compared with the controls, the high salt group, but not the low salt or eplerenone groups, developed significant myocardial damage. In the second set of experiments three groups of animals were studied: (1) L-NAME/Ang II/1%NaCl (high salt group) (2) L-NAME/Ang II/1%NaCl/eplerenone (eplerenone group), and (3) L-NAME/Ang II/1%NaCl with an extra 1% KCl in food (high dietary potassium group). Eplerenone, but not dietary potassium supplementation, prevented the development of cardiac damage.
Thus, mineralocorticoid receptor antagonist treatment and low sodium diet were effective in preventing cardiac damage, which suggests that a minimal level of aldosterone and a moderately high sodium diet are both required for the development of the cardiovascular damage in the L-NAME/Ang II model. The inability of potassium supplementation to reduce myocardial damage suggests that eplerenone’s protective effect is not due to its potassium-sparing ability, but is rather related to some other feature of its selective aldosterone antagonism.
Key Words: sodium • potassium • cardiovascular diseases • aldosterone • rats
This article has been cited by other articles:
 |
|
 |
|
  J. M. Luther, Z. Wang, J. Ma, N. Makhanova, H.-S. Kim, and N. J. Brown Endogenous Aldosterone Contributes to Acute Angiotensin II-Stimulated Plasminogen Activator Inhibitor-1 and Preproendothelin-1 Expression in Heart But Not Aorta Endocrinology, May 1, 2009; 150(5): 2229 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wei, A. T. Whaley-Connell, J. Habibi, J. Rehmer, N. Rehmer, K. Patel, M. Hayden, V. DeMarco, C. M. Ferrario, J. A. Ibdah, et al. Mineralocorticoid Receptor Antagonism Attenuates Vascular Apoptosis and Injury via Rescuing Protein Kinase B Activation Hypertension, February 1, 2009; 53(2): 158 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ricchiuti, C. G Lian, E. M Oestreicher, L. Tran, J. R Stone, T. Yao, E. W Seely, G. H Williams, and G. K Adler Estradiol increases angiotensin II type 1 receptor in hearts of ovariectomized rats J. Endocrinol., January 1, 2009; 200(1): 75 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Pojoga, T. M. Yao, S. Sinha, R. L. Ross, J. C. Lin, J. D. Raffetto, G. K. Adler, G. H. Williams, and R. A. Khalil Effect of dietary sodium on vasoconstriction and eNOS-mediated vascular relaxation in caveolin-1-deficient mice Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1258 - H1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown Aldosterone and Vascular Inflammation Hypertension, February 1, 2008; 51(2): 161 - 167. [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Ortiz, M. L. Graciano, J. J. Mullins, and K. D. Mitchell Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension, in Cyp1a1-Ren2 transgenic rats Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1584 - F1591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Stas, A. Whaley-Connell, J. Habibi, L. Appesh, M. R. Hayden, P. R. Karuparthi, M. Qazi, E. M. Morris, S. A. Cooper, C. D. Link, et al. Mineralocorticoid Receptor Blockade Attenuates Chronic Overexpression of the Renin-Angiotensin-Aldosterone System Stimulation of Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Cardiac Remodeling Endocrinology, August 1, 2007; 148(8): 3773 - 3780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Ortiz, M. L. Graciano, D. Seth, M. S. Awayda, and L. G. Navar Aldosterone receptor antagonism exacerbates intrarenal angiotensin II augmentation in ANG II-dependent hypertension Am J Physiol Renal Physiol, July 1, 2007; 293(1): F139 - F147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Adler and G. H. Williams Aldosterone: Villain or Protector? Hypertension, July 1, 2007; 50(1): 31 - 32. [Full Text] [PDF]
|
|
|
|
|
|
Z. Li, J. Y. Ma, I. Kerr, S. Chakravarty, S. Dugar, G. Schreiner, and A. A. Protter Selective inhibition of p38{alpha} MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1972 - H1977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Pimenta and D. A. Calhoun Aldosterone, Dietary Salt, and Renal Disease Hypertension, August 1, 2006; 48(2): 209 - 210. [Full Text] [PDF]
|
|
|
|
 |
|
 F. E. Nwariaku, B. S. Miller, R. Auchus, S. Holt, L. Watumull, B. Dolmatch, S. Nesbitt, W. Vongpatanasin, R. Victor, F. Wians, et al. Primary Hyperaldosteronism: Effect of Adrenal Vein Sampling on Surgical Outcome Arch Surg, May 1, 2006; 141(5): 497 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin Effects of Aldosterone on the Vasculature Hypertension, March 1, 2006; 47(3): 312 - 318. [Full Text] [PDF]
|
|
|
|
|
|
J. Ma, F. Albornoz, C. Yu, D. W. Byrne, D. E. Vaughan, and N. J. Brown Differing Effects of Mineralocorticoid Receptor-Dependent and -Independent Potassium-Sparing Diuretics on Fibrinolytic Balance Hypertension, August 1, 2005; 46(2): 313 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Williams Cardiovascular Benefits of Aldosterone Receptor Antagonists: What About Potassium? Hypertension, August 1, 2005; 46(2): 265 - 266. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Susic, J. Varagic, J. Ahn, L. C. Matavelli, and E. D. Frohlich Beneficial Cardiovascular Actions of Eplerenone in the Spontaneously Hypertensive Rat Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2005; 10(3): 197 - 203. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Bourraindeloup, C. Adamy, G. Candiani, M. Cailleret, M.-C. Bourin, T. Badoual, J. B. Su, S. Adubeiro, F. Roudot-Thoraval, J.-L. Dubois-Rande, et al. N-Acetylcysteine Treatment Normalizes Serum Tumor Necrosis Factor-{alpha} Level and Hinders the Progression of Cardiac Injury in Hypertensive Rats Circulation, October 5, 2004; 110(14): 2003 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dikow, L. P. Kihm, M. Zeier, J. Kapitza, J. Tornig, K. Amann, C. Tiefenbacher, and E. Ritz Increased Infarct Size in Uremic Rats: Reduced Ischemia Tolerance? J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1530 - 1536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D Struthers and T. M MacDonald Review of aldosterone- and angiotensin II-induced target organ damage and prevention Cardiovasc Res, March 1, 2004; 61(4): 663 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. de Paula, A. A. da Silva, and J. E. Hall Aldosterone Antagonism Attenuates Obesity-Induced Hypertension and Glomerular Hyperfiltration Hypertension, January 1, 2004; 43(1): 41 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Epstein Aldosterone receptor blockade and the role of eplerenone: evolving perspectives Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1984 - 1992. [Full Text] [PDF]
|
|
|
|
 |
|
 K. T Weber, Yao Sun, L. A Wodi, A. Munir, E. Jahangir, R. A Ahokas, I. C Gerling, A. E Postlethwaite, and K. J Warrington Toward a broader understanding of aldosterone in congestive heart failure Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 155 - 163. [Abstract] [PDF]
|
|
|
|
|
|
I. C. Gerling, Y. Sun, R. A. Ahokas, L. A. Wodi, S. K. Bhattacharya, K. J. Warrington, A. E. Postlethwaite, and K. T. Weber Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H813 - H821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qin, A. E. Rudolph, B. R. Bond, R. Rocha, E. A.G. Blomme, J. J. Goellner, J. W. Funder, and E. G. McMahon Transgenic Model of Aldosterone-Driven Cardiac Hypertrophy and Heart Failure Circ. Res., July 11, 2003; 93(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Williams and G. H. Williams 50th Anniversary of Aldosterone J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2364 - 2372. [Full Text] [PDF]
|
|
|
|
|
|
W. F. Young Jr. Minireview: Primary Aldosteronism--Changing Concepts in Diagnosis and Treatment Endocrinology, June 1, 2003; 144(6): 2208 - 2213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Young, L. Moussa, R. Dilley, and J. W. Funder Early Inflammatory Responses in Experimental Cardiac Hypertrophy and Fibrosis: Effects of 11{beta}-Hydroxysteroid Dehydrogenase Inactivation Endocrinology, March 1, 2003; 144(3): 1121 - 1125. [Abstract] [Full Text] [PDF]
|
|